IDiyas

For the Inventor, By the Inventor

Osaka, Japan

Seiji Kamioka

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 5.1

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Toyonaka, JP (2022)
  • Osaka, JP (2019 - 2024)

Company Filing History:

goldMedal7 out of 64 
 
Sumitomo Pharma Co., Ltd.
 patents
silverMedal6 out of 110 
 
Sumitomo Dainippon Pharma Co., Ltd.
 patents
bronzeMedal2 out of 19 
 
Boston Biomedical, Inc.
 patents
4. 1 out of 11 
 
Sumitomo Dainippon Pharma Oncology, Inc.
 patents
5. 1 out of 11 
 
Sumitomo Pharma Oncology, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents
1. 12410154 - 5-heteroaryl-1H-pyrazol-3-amine derivative (2025-09-09),
2. 12398149 - Dihydrochromene derivatives (2025-08-26),
3. 12263167 - Optically active azabicyclo ring derivative (2025-04-01),
4. 11911381 - Optically active azabicyclo ring derivative (2024-02-27),
5. 11639357 - Dihydrochromene derivatives (2023-05-02),
6. 11564920 - 5-heteroaryl-1H-pyrazol-3-amine derivative (2023-01-31),
7. 11414394 - Process for producing a hydrate of a hydrochloride salt of 2,2'-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid (2022-08-16),
8. 11369605 - Optically active azabicyclo ring derivative (2022-06-28),
9. 11325921 - Optically active crosslinked cyclic secondary amine derivative (2022-05-10),
10. 10934309 - Tricyclic quinone derivative (2021-03-02),
11. 10815241 - Optically active azabicyclo ring derivative (2020-10-27),
12. 10807993 - Dihydrochromene derivatives (2020-10-20),
13. 10800752 - Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer (2020-10-13),
14. 10183925 - Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer (2019-01-22),

Title: Seiji Kamioka: Innovator in Anticancer Compounds

Introduction

Seiji Kamioka is a prominent inventor based in Osaka, Japan, known for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, he has made remarkable strides in developing compounds that target cancer treatment.

Latest Patents

Among his latest innovations, Kamioka has developed a compound known as 5-heteroaryl-1H-pyrazol-3-amine derivative. This compound exhibits anticancer action through CHK1 inhibition, showcasing its potential as a powerful therapeutic agent. The research revealed that this compound, represented by a specific formula, demonstrates excellent antitumor action due to its potent inhibitory effects against CHK1. Another notable invention is the dihydrochromene derivatives, which serve as novel anti-tumor agents targeting cancer stem cells (CSCs). These compounds are designed to combat the persistent proliferation of malignant tumors, metastasis, and resistance to existing anti-tumor agents.

Career Highlights

Kamioka has worked with reputable companies such as Sumitomo Pharma Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd. His work in these organizations has significantly influenced the development of innovative cancer treatments.

Collaborations

Throughout his career, Kamioka has collaborated with esteemed colleagues, including Hitoshi Ban and Naoaki Shimada. These partnerships have fostered a collaborative environment that enhances research and development in the pharmaceutical industry.

Conclusion

Seiji Kamioka's contributions to cancer research and drug development highlight his role as a leading inventor in the pharmaceutical field. His innovative compounds and collaborations continue to pave the way for advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…